Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Journal: The New England journal of medicine
Published: May 28, 2024
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Journal: Science translational medicine
Published: December 23, 2021
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 10, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Journal: The New England journal of medicine
Published: July 14, 2021
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
Journal: medRxiv : the preprint server for health sciences
Published: June 23, 2021
Showing 1-6 of 6
Last Updated: 09/26/2026